Partner Headlines - BMY

  1. Investing Action Plan: Apple, Facebook, Amazon, Big Oil, Boeing, ...

    Investors Business Daily
  2. 5 Big Drugmakers Reporting Earnings Next Week

    Investors Business Daily
  3. Ken Fisher's Best Investments: Credicorp, Ambev, Tata Motors

    GuruFocus
  4. Bristol-Myers Looks To A Promising Future

    Benzinga
  5. Barron's Picks And Pans: Bristol-Myers Squibb, KeyCorp, Core-Mark ...

    Benzinga
  6. Intercept Pharma Spikes On Report That It’s Exploring A Sale

    IBD
  7. Earnings Recap For January 28

    Benzinga
  8. Bristol Myers Ticks Higher Following Q4 Beat, Encouraging Guidance

    Benzinga
  9. 10 Fund Managers Are Totally Wrong on GlaxoSmithKline

    GuruFocus
  10. JNJ Kicks Off Health Care Earnings—What About Deals, Buybacks?

    Benzinga
  11. Stock Marquee Crowded With Oil, Apple, and the Fed

    Benzinga
  12. Benzinga's Top Downgrades

    Benzinga
  13. Bristol-Myers Squibb's Opdivo + Yervoy Receives Expanded FDA ...

    Benzinga
  14. Benzinga's Top Upgrades

    Benzinga
  15. Fast Money Traders Share Their Biotech Picks

    Benzinga
  16. Dual Therapeutics Announces Oncology Strategic Collaboration ...

    GuruFocus
  17. Mylan, Momenta Team Up To Develop Biosimilar Drugs

    IBD
  18. 3 Potential Blockbuster Drugs Launching in 2016

    IBD
  19. Lilly Guidance Misses Estimates On Lower Sales

    IBD
  20. Baxalta Cuts Cancer Deal As Shire Circles Nearer

    IBD
  21. 5 Top Stocks of the Outperforming Vanguard Health Care Fund

    GuruFocus
  22. Glaxo's ViiV Acquiring Bristol-Myers' HIV Candidates

    IBD
  23. Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV Healthcare ...

    Benzinga
  24. Strategic Beta ETFs Among Year's Top Performers

    IBD
  25. Fast Money Picks For December 15

    Benzinga
  26. Signature Select Sells Stake in SPDR Gold Trust

    GuruFocus
  27. Bristol-Myers Squibb CompanyNew Longer-Term Data for Empliciti ...

    Benzinga
  28. Amgen Expands Work With Merck, Files Biosimilar In EU

    IBD
  29. Bristol-Myers Squibb's

    IBD
  30. Bristol-Myers Plans Projects

    IBD
  31. Bristol-Myers Looks Beyond Cancer To Build Portfolio

    IBD
  32. Bristol-Myers Squibb Announces U.S. Food and Drug Administration ...

    Benzinga
  33. Goldman Sachs' Top 4 Smid-Cap Biotech Picks

    IBD
  34. Gilead Seen Staying Top Dog In HCV, But Merck Rising

    IBD
  35. BRISTOL-MYERS SQUIBB'S

    IBD
  36. Pamela Anderson And Hepatitis C: Which Drug Makers Are Working ...

    Benzinga
  37. Celgene Reports Mixed Q3 As Cancer Rivals Rise

    IBD
  38. Celgene Reports Mixed Q3 As Cancer Rivals Rise

    IBD
  39. How This Top Stock Mutual Fund Manager Seeks Growth

    IBD
  40. How This Top Stock Mutual Fund Manager Seeks Growth

    IBD
  41. Bristol-Myers Squibb

    IBD
  42. Gilead Outlook Disappoints

    IBD
  43. 4 Drugmakers Who Beat Q3 Estimates Tuesday

    IBD
  44. These Three Pharma Giants Just Crushed Earnings

    Benzinga
  45. Earnings Scheduled For October 27, 2015

    Benzinga
  46. Earnings Boom This Week: Big Pharma, E-Commerce Giant BABA And ...

    Benzinga
  47. Fed Meeting A Mid-Week Bump In Flurry Of Earnings News

    Benzinga
  48. Eli Lilly Q3 Earnings, Guidance Beat On Cost Control

    IBD
  49. Bristol-Myers Squibb Says NICE Recommends Daklinza for Treatment ...

    Benzinga
  50. Mid-Afternoon Market Update: Dow Jumps 175 Points; Garmin Shares ...

    Benzinga
  51. Mid-Day Market Update: Crude Oil Down 2%; Five Prime Therapeutics ...

    Benzinga
  52. Benzinga's Volume Movers

    Benzinga
  53. Mid-Morning Market Update: Markets Rise; Citigroup Profit Tops ...

    Benzinga
  54. Morning Market Gainers

    Benzinga
  55. Benzinga's Top #PreMarket Gainers

    Benzinga
  56. Bristol-Myers Squibb, Five Prime Therapeutics Announce Worldwide ...

    Benzinga
  57. Five Prime Therapeutics to Host Conference Call on Worldwide ...

    Benzinga
  58. Bristol-Myers drug approved

    IBD
  59. Bristol-Myers' Opdivo Gets Another Early Approval

    IBD
  60. Full SEC Comments Regarding Bristol-Myers Squibb FCPA Violations

    Benzinga
  61. Facebook, Netflix Top Goldman Sachs' 2016 Growth List

    IBD
  62. Alexion, Vertex Steal Mo Stanley's Eyes From Gilead

    IBD
  63. Fast Money Picks For October 2

    Benzinga
  64. Bristol-Myers Squibb Receives Approval from the U.S. Food and ...

    Benzinga
  65. 3 Big Drugs Likely To Hit The Market Soon

    IBD
  66. Bristol-Myers, J&J Upgraded On New Drug Prospects

    IBD
  67. Benzinga's Top Upgrades

    Benzinga
  68. Yahoo PT Cut Despite Alibaba; McDonald's Upgraded

    IBD
  69. Wall Street Ends Mixed After Seesaw Session

    FoxBusiness
  70. Opdivo (nivolumab) Demonstrates Long Term Survival Benefit in ...

    Benzinga
  71. Arrowhead Hits Target In Hepatitis B Drug Trial

    IBD
  72. Fast Money Picks For September 21

    Benzinga
  73. Make The World A Better Place With...Stock Picks?

    Benzinga
  74. Jim Cramer Shares His Thoughts On Home Depot, Bristol-Myers Squibb, ...

    Benzinga
  75. Amgen And Biogen Lead Short Interest Surge In Biotechs

    Benzinga
  76. Designing the Appropriate Common Stock Retirement Portfolio: ...

    GuruFocus
  77. Fast Money Picks For September 10

    Benzinga
  78. Mike Khouw Sees Unusual Options Activity In Bristol-Myers Squibb

    Benzinga
  79. BMY Announces CheckMate -017, -063 Trials Evaluating Opdivo in ...

    Benzinga
  80. BMY Announces Opdivo+Yervoy Dosing Schedules Showed Acceptable ...

    Benzinga
  81. Bristol-Myers Squibb to Host Investor Teleconference to Discuss ...

    Benzinga
  82. U.S. Food and Drug Administration Accepts for Priority Review ...

    Benzinga
  83. Benzinga's M&A Chatter for Thursday August 27, 2015

    Benzinga
  84. Allied-Bristol Life Sciences Licenses Platform Technology and ...

    Benzinga
  85. Weekly Insider Sells Highlight: IMS, NOW, BMY, EA

    GuruFocus
  86. uniQure Receives Additional $53M from Bristol-Myers Squibb for ...

    Benzinga
  87. Gilead Q2 Earnings Soar As HCV Shines, HIV Rebounds

    IBD
  88. Pfizer, Merck Beat Q2 Views; Sanofi Makes PD-1 Deal

    IBD
  89. Biogen's Big-Volume Plunge Marks End Of 5-Year Run

    IBD
  90. Valeant Posts Princely Gains

    IBD
  91. Bristol-Myers Q2 profit jumps

    IBD
  92. 3 Big-Cap Drugmakers Who Beat Q2 Earnings Estimates

    IBD
  93. Shire Lifts 2015 Guidance On Strong Drug Pipeline

    IBD
  94. Lilly, Bristol-Myers Beat Q2 Views, Lift Guidance

    IBD
  95. Valeant Earnings Soar On M&A, Organic Sales Growth

    IBD
  96. Bristol-Myers Squibb Posts Upbeat Q2 Results, Lifts Profit Forecast

    Benzinga
  97. Stock Futures Up, But Volatile; SanDisk, Cirrus, Fortinet Soar

    IBD
  98. US Stock Futures Rise Ahead Of General Motors, McDonald's Earnings

    Benzinga
  99. European Medicines Agency Validates Two Parallel Type II Variation ...

    Benzinga
  100. Bristol Myers Announces EMA Validates Two Parallel Type II Variation ...

    Benzinga
Trading Center